Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

α-Helical peptidic scaffolds to target α-synuclein toxic species with nanomolar affinity

  • Santos, Jaime
  • Gracia, Pablo
  • Navarro, Susanna
  • Peña-Díaz, Samuel
  • Pujols, Jordi
  • Cremades, Nunilo
  • Pallarés, Irantzu
  • Ventura, Salvador
14 pags., 6 figs., α-Synuclein aggregation is a key driver of neurodegeneration in Parkinson’s disease and related syndromes. Accordingly, obtaining a molecule that targets α-synuclein toxic assemblies with high affinity is a long-pursued objective. Here, we exploit the biophysical properties of toxic oligomers and amyloid fibrils to identify a family of α-helical peptides that bind to these α-synuclein species with low nanomolar affinity, without interfering with the monomeric functional protein. This activity is translated into a high anti-aggregation potency and the ability to abrogate oligomer-induced cell damage. Using a structure-guided search we identify a human peptide expressed in the brain and the gastrointestinal tract with analogous binding, anti-aggregation, and detoxifying properties. The chemical entities we describe here may represent a therapeutic avenue for the synucleinopathies and are promising tools to assist diagnosis by discriminating between native and toxic α-synuclein species., This work was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) BIO2016-78310-R and BIO2017-91475-EXP to S.V, by the Ministry of Science and Innovation (MICINN) PID2019-105017RB-I00 to S.V, by ICREA, ICREA-Academia 2015 to S.V. N.C. was supported by MINECO RYC-2012-12068, MINECO/FEDER, EU BFU2015-64119-P and MICIU/FEDER, EU PGC2018-096335-B-100. J.S. was supported by MICINN via a doctoral grant (FPU17/01157).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An α-helical peptide-based plasmonic biosensor for highly specific detection of α-synuclein toxic oligomers

  • Giarola, Juliana Fátima
  • Santos, Jaime
  • Estévez, M. Carmen
  • Ventura, Salvador
  • Pallarès, Irantzu
  • Lechuga, Laura M.
[Background] α-Synuclein (αS) aggregation is the main neurological hallmark of a group of neurodegenerative disorders, collectively referred to as synucleinopathies, of which Parkinson's disease (PD) is the most prevalent. αS oligomers are elevated in the cerebrospinal fluid (CSF) of PD patients, standing as a biomarker for disease diagnosis. However, methods for early PD detection are still lacking. We have recently identified the amphipathic 22-residue peptide PSMα3 as a high-affinity binder of αS toxic oligomers. PSMα3 displayed excellent selectivity and reproducibility, binding to αS toxic oligomers with affinities in the low nanomolar range and without detectable cross-reactivity with functional monomeric αS., [Results] In this work, we leveraged these PSMα3 unique properties to design a plasmonic-based biosensor for the direct detection of toxic oligomers under label-free conditions., [Significance and novelty] We describe the integration of the peptide in a lab-on-a-chip plasmonic platform suitable for point-of-care measurements of αS toxic oligomers in CSF samples in real-time and at an affordable cost, providing an innovative biosensor for PD early diagnosis in the clinic., This work was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) BIO2016-78310-R and BIO2017-91475-EXP to S.V, by the Ministry of Science and Innovation (MICINN) PID2019-105017RB-I00 to S.V, by ICREA, ICREA-Academia 2015 to S.V. J.S. was supported by MICINN via a doctoral grant (FPU17/01157). ICN2 is funded by the CERCA programme/Generalitat de Catalunya). The ICN2 is supported by Severo Ochoa Centres of Excellence programme, Grant CEX2021-001214-S, funded by MCIN/AEI/10.13039.501100011033. The NanoB2A group is a consolidated research group (Grup de Recerca) of the Generalitat de Catalunya and has support from the Departament de Recerca i Universitats de la Generalitat de Catalunya (expedient: 2021 SGR 00456)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001214-S)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

α-Helical peptidic scaffolds to target α-synuclein toxic species with nanomolar affinity

  • Santos Suárez, Jaime|||0000-0001-9045-7765
  • Gracia González, Pablo
  • Navarro, Susanna|||0000-0001-8160-9536
  • Peña Díaz, Samuel|||0000-0002-2902-823X
  • Pujols Pujol, Jordi|||0000-0001-9424-5866
  • Cremades, Nunilo|||0000-0002-9138-6687
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Ventura, Salvador|||0000-0002-9652-6351
α-Synuclein aggregation is a key driver of neurodegeneration in Parkinson's disease and related syndromes. Accordingly, obtaining a molecule that targets α-synuclein toxic assemblies with high affinity is a long-pursued objective. Here, we exploit the biophysical properties of toxic oligomers and amyloid fibrils to identify a family of α-helical peptides that bind to these α-synuclein species with low nanomolar affinity, without interfering with the monomeric functional protein. This activity is translated into a high anti-aggregation potency and the ability to abrogate oligomer-induced cell damage. Using a structure-guided search we identify a human peptide expressed in the brain and the gastrointestinal tract with analogous binding, anti-aggregation, and detoxifying properties. The chemical entities we describe here may represent a therapeutic avenue for the synucleinopathies and are promising tools to assist diagnosis by discriminating between native and toxic α-synuclein species. α-Synuclein (αS) aggregation is a driver of several neurodegenerative disorders. Here, the authors identify a class of peptides that bind toxic αS oligomers and amyloid fibrils but not monomeric functional protein, and prevent further αS aggregation and associated cell damage.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Amyloid Fibrils Formed by Short Prion-Inspired Peptides Are Metalloenzymes

  • Navarro, Susanna|||0000-0001-8160-9536
  • Díaz-Caballero, Marta|||0000-0001-9032-9819
  • Peccati, Francesca|||0000-0002-7813-8216
  • Roldán-Martín, Lorena|||0000-0002-6902-8285
  • Sodupe, Mariona|||0000-0003-0276-0524
  • Ventura, Salvador|||0000-0002-9652-6351
Enzymes typically fold into defined 3D protein structures exhibiting a high catalytic efficiency and selectivity. It has been proposed that the earliest enzymes may have arisen from the self-assembly of short peptides into supramolecular amyloid-like structures. Several artificial amyloids have been shown to display catalytic activity while offering advantages over natural enzymes in terms of modularity, flexibility, stability, and reusability. Hydrolases, especially esterases, are the most common artificial amyloid-like nanozymes with some reported to act as carbonic anhydrases (CA). Their hydrolytic activity is often dependent on the binding of metallic cofactors through a coordination triad composed of His residues in the β-strands, which mimic the arrangement found in natural metalloenzymes. Tyr residues contribute to the coordination of metal ions in the active center of metalloproteins; however, their use has been mostly neglected in the design of metal-containing amyloid-based nanozymes. We recently reported that four different polar prion-inspired heptapeptides spontaneously self-assembled into amyloid fibrils. Their sequences lack His but contain three alternate Tyr residues exposed to solvent. We combine experiments and simulations to demonstrate that the amyloid fibrils formed by these peptides can efficiently coordinate and retain different divalent metal cations, functioning as both metal scavengers and nanozymes. The metallized fibrils exhibit esterase and CA activities without the need for a histidine triad. These findings highlight the functional versatility of prion-inspired peptide assemblies and provide a new sequential context for the creation of artificial metalloenzymes. Furthermore, our data support amyloid-like structures acting as ancestral catalysts at the origin of life.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Targetable N-Terminal Motif Orchestrates α-Synuclein Oligomer-to-Fibril Conversion

  • Santos Suárez, Jaime|||0000-0001-9045-7765
  • Cuéllar, Jorge|||0000-0002-7789-807X
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Byrd, Emily|||0000-0002-9876-1400
  • Lends, Alons
  • Moro, Fernando
  • Abdul-Shukkoor, Muhammed Bilal
  • Pujols Pujol, Jordi|||0000-0001-9424-5866
  • Velasco-Carneros, Lorea|||0000-0002-1296-9498
  • Sobott, Frank|||0000-0001-9029-1865
  • Otzen, Daniel E.|||0000-0002-2918-8989
  • Calabrese, Antonio N.|||0000-0003-2437-7761
  • Muga, Arturo|||0000-0003-0345-6882
  • Pedersen, Jan Skov|||0000-0002-7768-0206
  • Loquet, Antoine|||0000-0001-7176-7813
  • Valpuesta, Jose María|||0000-0001-7468-8053
  • Radford, Sheena E.|||0000-0002-3079-8039
  • Ventura, Salvador|||0000-0002-9652-6351
Oligomeric species populated during α-synuclein aggregation are considered key drivers of neurodegeneration in Parkinson's disease. However, the development of oligomer-targeting therapeutics is constrained by our limited knowledge of their structure and the molecular determinants driving their conversion to fibrils. Phenol-soluble modulin α3 (PSMα3) is a nanomolar peptide binder of α-synuclein oligomers that inhibits aggregation by blocking oligomer-to-fibril conversion. Here, we investigate the binding of PSMα3 to α-synuclein oligomers to discover the mechanistic basis of this protective activity. We find that PSMα3 selectively targets an α-synuclein N-terminal motif (residues 36-61) that populates a distinct conformation in the mono- and oligomeric states. This α-synuclein region plays a pivotal role in oligomer-to-fibril conversion as its absence renders the central NAC domain insufficient to prompt this structural transition. The hereditary mutation G51D, associated with early onset Parkinson's disease, causes a conformational fluctuation in this region, leading to delayed oligomer-to-fibril conversion and an accumulation of oligomers that are resistant to remodeling by molecular chaperones. Overall, our findings unveil a new targetable region in α-synuclein oligomers, advance our comprehension of oligomer-to-amyloid fibril conversion, and reveal a new facet of α-synuclein pathogenic mutations.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

An α-helical peptide-based plasmonic biosensor for highly specific detection of α-synuclein toxic oligomers

  • Giarola, Juliana Fatima|||0000-0002-2121-0328
  • Santos Suárez, Jaime|||0000-0001-9045-7765
  • Estévez, M. Carmen|||0000-0003-3694-7186
  • Ventura, Salvador|||0000-0002-9652-6351
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Lechuga, Laura M.|||0000-0001-5187-5358
Background: α-Synuclein (αS) aggregation is the main neurological hallmark of a group of neurodegenerative disorders, collectively referred to as synucleinopathies, of which Parkinson's disease (PD) is the most prevalent. αS oligomers are elevated in the cerebrospinal fluid (CSF) of PD patients, standing as a biomarker for disease diagnosis. However, methods for early PD detection are still lacking. We have recently identified the amphipathic 22-residue peptide PSMα3 as a high-affinity binder of αS toxic oligomers. PSMα3 displayed excellent selectivity and reproducibility, binding to αS toxic oligomers with affinities in the low nanomolar range and without detectable cross-reactivity with functional monomeric αS. Results: In this work, we leveraged these PSMα3 unique properties to design a plasmonic-based biosensor for the direct detection of toxic oligomers under label-free conditions. Significance and novelty: We describe the integration of the peptide in a lab-on-a-chip plasmonic platform suitable for point-of-care measurements of αS toxic oligomers in CSF samples in real-time and at an affordable cost, providing an innovative biosensor for PD early diagnosis in the clinic.